Cargando…
Immunogenicity Evaluating of the Multivalent COVID-19 Inactivated Vaccine against the SARS-CoV-2 Variants
It has been reported that the novel coronavirus (COVID-19) has caused more than 286 million cases and 5.4 million deaths to date. Several strategies have been implemented globally, such as social distancing and the development of the vaccines. Several severe acute respiratory syndrome coronavirus 2...
Autores principales: | Zhang, Yuntao, Tan, Wenjie, Lou, Zhiyong, Huang, Baoying, Zhou, Weimin, Zhao, Yuxiu, Zhang, Jin, Liang, Hongyang, Li, Na, Zhu, Xiujuan, Ding, Ling, Guo, Yancen, He, Zhenyu, He, Yao, Wang, Zhanhui, Ma, Bo, Ma, Meng, Zhao, Suhua, Chang, Zhen, Zhao, Xue, Zheng, Xiaotong, Wu, Guizhen, Wang, Hui, Yang, Xiaoming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228943/ https://www.ncbi.nlm.nih.gov/pubmed/35746564 http://dx.doi.org/10.3390/vaccines10060956 |
Ejemplares similares
-
Vaccination with Omicron Inactivated Vaccine in Pre-vaccinated Mice Protects against SARS-CoV-2 Prototype and Omicron Variants
por: Zhang, Yuntao, et al.
Publicado: (2022) -
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial
por: Xia, ShengLi, et al.
Publicado: (2022) -
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
por: Wang, Hui, et al.
Publicado: (2020) -
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
por: Xia, Shengli, et al.
Publicado: (2021) -
Safety and immunogenicity of a combined DTacP-sIPV-Hib vaccine in animal models
por: Zhang, Yuntao, et al.
Publicado: (2022)